Biomarker technology is fundamentally reshaping how Alzheimer’s clinical trials are designed and executed. Rather than relying on expensive brain imaging or invasive spinal fluid tests, researchers can now use blood-based biomarkers—particularly phosphorylated tau proteins like p-tau217 and p-tau181—to identify participants, monitor disease progression, and measure treatment response. This shift isn’t theoretical: as of 2025, 84% of Alzheimer’s disease-targeted therapeutic trials now include fluid, imaging, or digital biomarkers as either an inclusion criterion or outcome measure, with blood tests increasingly becoming the preferred option due to their accuracy and accessibility.
The practical impact is substantial. In May 2025, the FDA cleared Fujirebio’s blood test to help diagnose Alzheimer’s disease, measuring two proteins with greater than 91% agreement with brain scans. By October 2025, Roche’s Elecsys test received FDA clearance for primary care use, making early detection available outside specialized medical centers. This article explores how these advances are reshaping trial design, what specific trials are implementing these tests, and what clinical care providers and patients need to understand about this rapid evolution.
Table of Contents
- How Are Blood-Based Biomarkers Transforming Trial Enrollment?
- Blood Tests as Biomarker Endpoints—What the Data Shows
- Regulatory Approvals Driving Trial Standardization
- Cost and Accessibility—Why Blood Tests Are Reshaping Economics
- The Biomarker Specificity Challenge—When Blood Tests Aren’t Specific Enough
- Active Trials and Real-World Implementation
- The Convergence Toward Integrated Biomarker Strategies
- Conclusion
How Are Blood-Based Biomarkers Transforming Trial Enrollment?
The traditional approach to recruiting Alzheimer’s trial participants relied on cognitive testing and brain imaging—methods that required participants to travel to medical centers, undergo lengthy scans, and wait weeks for results. Blood-based biomarkers have simplified this dramatically. A single venipuncture can now measure phosphorylated tau variants or amyloid-beta levels, with results available quickly and at a fraction of the cost. Currently, 58% of disease-targeted Alzheimer’s trials use biomarkers explicitly for participant inclusion criteria, meaning researchers can now pre-screen candidates before investing in expensive imaging or cognitive batteries.
This streamlining has accelerated trial timelines and reduced participant burden. The PRECISE-AD trial, for instance, uses plasma p-tau217 as its primary endpoint while investigating the amyloid-beta antibody PMN310, with a planned interim analysis in Q2 2026. Roche’s TRONTIER 1 and 2 Phase III trials investigating trontinemab in early Alzheimer’s disease employ the Elecsys p-tau217 pre-screening test (TRAVELLER study) to identify eligible participants before enrollment. These aren’t small operational changes—they represent a fundamental shift in how trial infrastructure is built. However, the accessibility advantage of blood tests can create a double-edged sword: trials can recruit more quickly, but researchers must maintain rigorous analytical standards to prevent false positives from confounding results.
Blood Tests as Biomarker Endpoints—What the Data Shows
Beyond participant screening, blood-based biomarkers are increasingly used as primary or secondary trial endpoints. A 2026 analysis found that plasma p-tau217 effect sizes support clinical trials detecting a 25% drug effect with 80% statistical power at the 0.05 significance level—meeting the bar for regulatory approval discussions. Additionally, changes in plasma p-tau181 and p-tau217 at the 6-month mark have been shown to correlate with clinical outcomes measured at 18 months, meaning researchers can potentially detect treatment signals earlier without waiting for cognitive decline to become clinically measurable. This represents a major advancement for trial design because it compresses timelines.
Traditionally, Alzheimer’s trials required 18-36 months of follow-up to detect meaningful cognitive slowing. Biomarker-based endpoints can show biological change in months. However, there’s an important caveat: elevated serum phosphorylated tau is not exclusive to Alzheimer’s disease. Patients with systemic amyloidosis also show elevated p-tau levels, requiring careful stratification strategies and confirmatory testing. A trial that relies solely on p-tau217 elevation without additional biomarkers or cognitive assessment risks enrolling participants with disease mimickers, potentially obscuring true treatment effects.
Regulatory Approvals Driving Trial Standardization
The FDA’s recent approvals for blood-based biomarker tests have created a regulatory framework that trials are now building around. When the FDA cleared Fujirebio’s test in May 2025 with 91% agreement to amyloid-PET imaging, it established a clinical standard that trial sponsors can reference. Similarly, Roche’s October 2025 Elecsys clearance for primary care means that community physicians—not just specialists—can now refer appropriate patients into trials. This democratization of access is changing recruitment geography; trials are no longer concentrated in tertiary academic centers.
The Alzheimer’s Association’s 2025 clinical practice guideline on blood-based biomarker use further standardizes trial operations by providing evidence-based recommendations for which populations should be tested and at what thresholds. Trials can now align their biomarker cutoffs with these published guidelines, reducing idiosyncratic design variations and improving cross-trial comparability. One emerging framework is the Treatment-Related Amyloid Clearance (TRAC) standard, which proposes uniform reflection of amyloid-beta deposit clearance using amyloid-PET imaging, potentially allowing trials to compare results more directly. Yet standardization always involves trade-offs: while uniform biomarker cutoffs enable meta-analyses and strengthen regulatory submissions, they may exclude patients with atypical presentations who would benefit from experimental treatments.
Cost and Accessibility—Why Blood Tests Are Reshaping Economics
Blood-based biomarkers are substantially cheaper and more accessible than positron emission tomography (PET) brain imaging or cerebrospinal fluid tests. A single p-tau217 blood test costs roughly $200-400 in a research setting, whereas a brain amyloid-PET scan costs $5,000-8,000 and requires specialized equipment available only at major medical centers. This cost difference has direct trial implications: recruitment budgets stretch further, sites in rural or underserved areas can participate without referral partnerships, and repeat sampling throughout a trial becomes financially feasible.
The Washington University study demonstrating that a single blood test can forecast Alzheimer’s symptom onset within 3-4 years illustrates the practical power of this accessibility shift. If a trial can predict cognitive decline probability from a single baseline blood draw, investigators can better stratify participants, control for disease stage heterogeneity, and potentially detect smaller treatment effects because the study population is more homogeneous. However, accessibility carries its own risk: the ease of conducting blood tests may lead to over-screening or inclusion of asymptomatic biomarker-positive individuals who may never develop symptoms. Trials must balance recruitment efficiency with scientific rigor, ensuring that biomarker positivity actually correlates with the disease stage they’re trying to treat.
The Biomarker Specificity Challenge—When Blood Tests Aren’t Specific Enough
While blood-based biomarkers have revolutionized trial design, they carry a critical limitation that trial designers must account for: phosphorylated tau elevation is not pathognomonic for Alzheimer’s disease. As noted in recent clinical trial literature, patients with systemic amyloidosis can also present with elevated p-tau levels. This overlap creates a stratification problem—a participant could pass a p-tau screening test but actually have systemic amyloidosis-related cognitive impairment, not Alzheimer’s disease.
Their response to an anti-amyloid or anti-tau therapeutic would be unpredictable and could dilute apparent treatment effects across the trial population. Sophisticated trial designs now address this by layering biomarkers: p-tau217 screening is often paired with amyloid-beta measurements, plasma phospho-tau/phospho-tau ratios, or imaging confirmation in borderline cases. This multi-marker approach increases specificity but reintroduces some of the complexity and cost that blood-based biomarkers initially simplified. The practical lesson for care providers and patients is that a positive blood biomarker test is not equivalent to an Alzheimer’s disease diagnosis—it’s a signal that warrants further evaluation with imaging or clinical assessment before enrolling in a disease-modifying therapy trial.
Active Trials and Real-World Implementation
Several ongoing trials are now using these biomarker advances in their operational designs. The PRECISE-AD trial exemplifies this approach, using plasma p-tau217 as a primary efficacy endpoint rather than relying solely on cognitive decline. Roche’s TRONTIER trials take a related approach, using pre-screening with the Elecsys p-tau217 test to enrich for participants most likely to benefit, then tracking treatment response via serial p-tau and amyloid-beta measurements. These trials are collecting not only efficacy data but also validation data on blood biomarkers as surrogate endpoints, which will inform future regulatory pathways.
The real-world implication is that participants in these trials often experience shorter screening periods, less travel burden, and more frequent biomarker monitoring—changing the lived experience of trial participation. A participant in a traditional imaging-based trial might undergo screening cognitive testing and one amyloid-PET scan before randomization. In a biomarker-centric trial like PRECISE-AD, that same participant might undergo two blood draws and cognitive testing, completing screening in days rather than weeks. This efficiency also means that trials can now monitor treatment response more granularly, detecting biological changes that inform dose adjustments or early stopping analyses.
The Convergence Toward Integrated Biomarker Strategies
The future of Alzheimer’s clinical trial design is moving toward integrated biomarker strategies that combine blood tests, imaging, cognitive assessments, and increasingly, digital biomarkers like gait or sleep patterns. The fact that 36% of current disease-targeted trials now use biomarkers as a primary outcome measure signals that this isn’t a peripheral development—it’s becoming the standard approach. As these trials accumulate data, the correlation between blood biomarker changes and clinical outcomes will strengthen, potentially allowing even faster, smaller trials for future therapeutics.
One forward-looking development is the use of p-tau217 effect sizes to power future trials more efficiently. If plasma p-tau217 change correlates reliably with 18-month cognitive outcomes, future trials might recruit smaller cohorts, run for shorter durations, and still achieve statistical significance. This acceleration could compress the time from drug discovery to clinical availability, though it also places enormous responsibility on the biomarker science to be accurate and reproducible across populations and labs.
Conclusion
Biomarker technology advances—particularly FDA-cleared blood tests for phosphorylated tau and amyloid-beta—are fundamentally reshaping how Alzheimer’s clinical trials identify participants, measure outcomes, and evaluate treatment efficacy. With 84% of current disease-targeted trials now incorporating fluid or imaging biomarkers, and blood-based tests becoming the preferred option due to cost, accessibility, and accuracy, trial design is shifting away from time-intensive brain imaging toward rapid, scalable blood testing. These advances enable faster recruitment, shorter screening periods, and more granular disease monitoring.
For patients and care providers, understanding these biomarker advances matters because it directly affects trial accessibility and the meaning of study results. Blood test results alone are not a diagnosis—they’re a signal that warrants clinical correlation and potentially imaging confirmation. As new trials like PRECISE-AD and TRONTIER increasingly use biomarkers as primary endpoints, the evidence base linking blood biomarker changes to clinical benefit will grow, potentially transforming how disease modification is monitored in both research and clinical care settings.
